REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 10
- Part 10: For the preceding part double click ID:nRSH4027Ri
Product Sales. This poses various challenges including: more volatile
economic conditions and/or political environments; competition from
multinational and local companies with existing market presence; the need
to identify and to leverage appropriate opportunities for sales and
marketing; poor IP protection; inadequate protection against crime
(including counterfeiting, corruption and fraud); inadequate
infrastructure to address disease outbreaks (such as the Ebola virus);
the need to impose developed market compliance standards; the need to
meet a more diverse range of national regulatory, clinical and
manufacturing requirements; inadvertent breaches of local and
international law; not being able to recruit appropriately skilled and
experienced personnel; identification of the most effective sales and
- More to follow, for following part double click ID:nRSH4027RkRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement